To correct technical errors in the enrollment of the bill H.R. 3580.

Mr. Speaker, I move to suspend the rules and agree to the concurrent resolution (H. Con. Res. 217) to correct technical errors in the enrollment of the bill H.R. 3580.

Mr. Speaker, once again I would ask unanimous consent that all Members may have 5 legislative days to revise and extend their remarks and include extraneous material on the resolution under consideration.

Mr. Speaker, I yield myself such time as I may consume.

Mr. Speaker, this resolution concerns two errors in the bill, H.R. 3580, the Food and Drug Administration Amendments of 2007. The bill has passed both the House and Senate and is currently in the process of being enrolled for delivery to the President.

The resolution directs the Clerk of the House to correct two errors, both of which were made in drafting and inadvertently occurred as we all worked under pressure to complete the drafting of H.R. 3580.

We were under pressure to complete that bill, as you know, before the expiration date on September 30 of PDUFA, the Prescription Drug User Fee Act. The failure to reauthorize PDUFA in time would have caused the Food and Drug Administration to send out notice of employee layoffs.

I'm aware of no objection to passage of the resolution, and I would urge my colleagues to support it.

Mr. Speaker, I reserve the balance of my time.

Mr. Speaker, once again I would urge passage of this corrections legislation. I have no further requests for time and yield back the balance of my time.

Mr. Speaker, I yield myself as much time as I may consume.

Mr. Speaker, H.R. 3580, which passed the House last week, was highly technical and addressed a number of very complicated FDA policy and regulatory matters. I commend the bipartisan Members and the staff who worked so hard on the language that passed with such broad support in the House. Inevitably, when these complicated matters are addressed, some drafting and technical issues need to be revisited in a technical corrections bill.

In the case of the FDA Amendments of 2007, we were especially mindful that the funding had to be secured to prevent the layoff of FDA reviewers prior to September 30. Given the importance of that deadline to protecting the public health, it is inevitable drafting and workability issues may need to be revisited. The resolution simply corrects two omissions from the text that was approved last week.

I yield back the balance of my time.